The company uses recombinantly engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules, to create more than 100 billion different Anticalins that can virtually bind to any target of interest. Pieris Pharmaceuticals focuses on the discovery and development of the Anticalin class of biotherapeutics, including PRS-080, PRS-060, PRS-343, and PRS-332, to help patients with cancer, severe asthma, anemia, and other medical conditions with a high unmet medical need. The company operates in the United States.